EcoR1 Capital, LLC Q3 2022 vs. Q4 2022 13F Holdings Comparison

In the world of finance, investments are a constantly changing game. One minute a stock is up, and the next it's down. Understanding these changes is essential to making sound investment decisions. EcoR1 Capital, LLC is a leading investment firm and has recently released their Q3 2022 vs. Q4 2022 13F holdings comparison. Let's take a closer look at the data and what it could mean for the future.

The Total Picture

EcoR1 Capital's Q3 2022 vs. Q4 2022 13F holdings comparison revealed interesting changes in holdings across multiple sectors. The total value of shares decreased by 2.4%, from $7,181,910 to $7,016,984.

Healthcare Sector

The healthcare sector saw some significant changes. One of the biggest increases in shares was for Revolution Medicines Inc, which had a surge of 198.9%, from 1,801,847 shares to 4,458,731 shares. This increase could be attributed to the company's recent release of positive clinical trial results. The top decrease in shares was for Apellis Pharmaceuticals, which saw a decline of -24.3%, from 5,183,431 shares to 2,680,035 shares. This decrease could be linked to the company's recent rejection for European approval of one of their medications.

Other Sectors

The technology sector saw a slight increase in shares, while the consumer cyclical and financial sectors saw a slight decrease. Companies such as Zai Lab Ltd and SpringWorks Therapeutics Inc had minor decreases in shares, while Kura Oncology Inc and Voyagers Therapeutics Inc saw slight increases.

Bottom Line

Overall, EcoR1 Capital's Q3 2022 vs. Q4 2022 13F holdings comparison shows a mix of minor increases and decreases in holdings across multiple sectors. These changes could be attributed to a number of factors such as market conditions, company performance, and changes in investor sentiment. EcoR1 Capital's careful management of their holdings will be closely watched as we head into the next quarter.

As always, investors should do their due diligence before making any investment decisions and should consider factors such as their personal financial situation, risk tolerance, and investment goals. EcoR1's Q3 2022 vs. Q4 2022 13F holdings comparison provides valuable insights and should be used as a tool to inform, but not dictate an investor's decisions.